Bryan Giraudo has served as the Chief Financial Officer of Gossamerbio since May 2018 and Chief Operating Officer since September 2021. Bryan has completed nearly $1.0 billion in financings for Gossamer since inception from Series B, thru IPO and additional debt and equity financings. Prior to joining Gossamer, Mr. Giraudo was a Senior Managing Director at Leerink Partners (now known as SVB Leerink) from 2009 to April 2018, where he was responsible for their western North America and Asia Pacific biotechnology and medical technology banking practice. Before joining Leerink, Mr. Giraudo was a Managing Director in Merrill Lynch and Co.’s Global Healthcare Investment Banking Group. He joined Merrill Lynch in 1997. As a banker, he has completed over 200 corporate finance, corporate partnership and strategic advisory transactions. He has been a member of the board of directors of Protagonist Therapeutics, Inc. since May 2018 and Onxeo SA since November 2021. Mr. Giraudo received his B.A. from Georgetown University.